- ADMA Biologics Investors Should Contact Block & Leviton to Possibly Recover Losses Through The Firm's Investigation
May 11, 2026 · newsfilecorp.com
Boston, Massachusetts--(Newsfile Corp. - May 11, 2026) - Block & Leviton is investigating ADMA Biologics, Inc. (NASDAQ: ADMA) for potential securities law violations. Investors who have lost money in their ADMA Biologics, Inc. investment should contact the firm to learn more about how they might recover those losses.
- ADMA BIOLOGICS INVESTORS SHOULD CONTACT BLOCK & LEVITON TO POSSIBLY RECOVER LOSSES THROUGH THE FIRM'S INVESTIGATION
May 11, 2026
BOSTON, MASSACHUSETTS--(NEWSFILE CORP. - MAY 11, 2026) - BLOCK & LEVITON IS INVESTIGATING ADMA BIOLOGICS, INC. (NASDAQ: ADMA) FOR POTENTIAL SECURITIES LAW VIOLATIONS. INVESTORS WHO HAVE LOST MONEY IN THEIR ADMA BIOLOGICS, INC. INVESTMENT SHOULD CONTACT THE FIRM TO LEARN MORE ABOUT HOW THEY MIGHT RECOVER THOSE LOSSES.
- $ADMA Investigation Reminder: ADMA Biologics Investigation on behalf of Investors is Ongoing – Contact BFA Law if You Lost Money
May 11, 2026
NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws.
If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit.
Why is ADMA Biologics Being Investigated for Securities Fraud?
ADMA Biologics is an end-to-end commercial biopharmaceutical company focused on manufacturing and developing specialty biologics. ADMA Biologics’ flagship product is ASCENIV, a liquid immune globulin solution used to treat Primary Humoral Immunodeficiency in adults and adolescents.
BFA is investigating allegations that ADMA Biologics’ reported 20% revenue growth in 2025 was driven by a channel stuffing scheme to mask deteriorating demand.
Why did ADMA Biologics’ Stock Drop?
On March 24, 2026, Culper Research, an investigative research firm, published a report titled “ADMA Biologics Inc (ADMA): Channel Stuffing, an Undisclosed Related Party Distributor, and –3% Real Growth in 2025 vs. +20% Reported.” The report revealed, among other things, that in 2025 ADMA Biologics induced one of its distributors to “stock excess ASCENIV by offering rebates and extended payment terms in order to meet order expectations.” This allegedly allowed ADMA Biologics to book revenue and “report[] growth that was never there.” According to Culper Research, had ADMA Biologics not engaged in this alleged channel stuffing scheme, it would have experienced revenue declines of 3% in 2025 instead of the reported 20% growth.
This news caused the price of ADMA Biologics stock to decline $3.96 per share, or 29%, over the course of two trading days, from $13.59 per share on March 23, 2026, to $9.63 per share on March 25, 2026.
Click here for more information:https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit.
What Can You Do?
If you invested in ADMA Biologics, you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit
Or contact:
Adam McCall
adam@bfalaw.com
212.789.3619
Why Bleichmar Fonti & Auld LLP?
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit
Attorney advertising. Past results do not guarantee future outcomes.
- New Strong Sell Stocks for May 11th
May 11, 2026
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:
ADMA Biologics, Inc. ADMA is a biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 12.5% downward over the last 60 days.
Aptiv PLC APTV is a manufacturer and seller of vehicle components. The Zacks Consensus Estimate for its current year earnings has been revised 24.1% downward over the last 60 days.Top of FormBottom of Form
Astec Industries, Inc. ASTE is a manufacturer of road building and construction equipment and components. The Zacks Consensus Estimate for its current year earnings has been revised nearly 4% downward over the last 60 days.
View the entire Zacks Rank #5 List.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Astec Industries, Inc. (ASTE) : Free Stock Analysis Report
ADMA Biologics Inc (ADMA) : Free Stock Analysis Report
Aptiv PLC (APTV) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
View Comments
- New Strong Sell Stocks for May 11th
May 11, 2026
Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:
ADMA Biologics, Inc. ADMA is a biopharmaceutical company. The Zacks Consensus Estimate for its current year earnings has been revised 12.5% downward over the last 60 days.
Aptiv PLC APTV is a manufacturer and seller of vehicle components. The Zacks Consensus Estimate for its current year earnings has been revised 24.1% downward over the last 60 days.Top of FormBottom of Form
Astec Industries, Inc. ASTE is a manufacturer of road building and construction equipment and components. The Zacks Consensus Estimate for its current year earnings has been revised nearly 4% downward over the last 60 days.
View the entire Zacks Rank #5 List.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Astec Industries, Inc. (ASTE) : Free Stock Analysis Report
ADMA Biologics Inc (ADMA) : Free Stock Analysis Report
Aptiv PLC (APTV) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
- New Strong Sell Stocks for May 11th
May 11, 2026 · zacks.com
ADMA, APTV and ASTE have been added to the Zacks Rank #5 (Strong Sell) List on May 11th, 2026.
- $ADMA Investigation Reminder: ADMA Biologics Investigation on behalf of Investors is Ongoing – Contact BFA Law if You Lost Money
May 11, 2026 · globenewswire.com
NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit.
- $ADMA INVESTIGATION REMINDER: ADMA BIOLOGICS INVESTIGATION ON BEHALF OF INVESTORS IS ONGOING – CONTACT BFA LAW IF YOU LOST MONEY
May 11, 2026
NEW YORK, MAY 11, 2026 (GLOBE NEWSWIRE) -- LEADING SECURITIES LAW FIRM BLEICHMAR FONTI & AULD LLP ANNOUNCES AN INVESTIGATION INTO ADMA BIOLOGICS, INC. (NASDAQ:ADMA) FOR POTENTIAL VIOLATIONS OF THE FEDERAL SECURITIES LAWS. IF YOU INVESTED IN ADMA BIOLOGICS, YOU ARE ENCOURAGED TO OBTAIN ADDITIONAL INFORMATION BY VISITING: HTTPS://WWW.BFALAW.COM/CASES/ADMA-BIOLOGICS-CLASS-ACTION-LAWSUIT.
- ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
May 10, 2026
NEW YORK, May 10, 2026 (GLOBE NEWSWIRE) --
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the investing public.
SO WHAT: If you purchased ADMA Biologics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=57940 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.
WHAT IS THIS ABOUT: On March 24, 2026, Investing.com published an article entitled “ADMA Biologics shares plunge on short seller allegations.” The article stated that ADMA Biologics shares fell “after short seller Culper Research released a report alleging the company engaged in channel stuffing to inflate revenue growth.”
On this news, ADMA Biologics stock fell 16.6% on March 24, 2026.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
case@rosenlegal.com
www.rosenlegal.com
- ADMA Investor News: If You Have Suffered Losses in ADMA Biologics, Inc. (NASDAQ: ADMA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
May 10, 2026 · globenewswire.com
NEW YORK, May 10, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the investing public.
